Cellerant Therapeutics Appoints Timothy C. Fong, Ph.D., Vice President of Research; Linda F. Rogers Named Senior Director of Global Clinical Operations.

Business Editors/Health/Medical Writers

BIOWIRE2K

PALO ALTO, Calif.--(BUSINESS WIRE)--June 2, 2004

Cellerant Therapeutics Inc. announced that it has made two key appointments to its research team that is focused on developing therapies based on hematopoietic stem cells (HSCs). Timothy C. Fong, Ph.D., has been named Vice President of Research. Dr. Fong was most recently the Vice President, Discovery Research at SangStat Medical Corporation. Additionally, Linda F. Rogers, R.N., was named Senior Director of Global Clinical Operations. Ms. Rogers was most recently Director, Clinical Operations of SangStat Medical Corporation.

"Dr. Fong and Ms. Rogers bring significant research and clinical trial management expertise to Cellerant in the areas of hematology, oncology and transplantation," commented Bruce Cohen, President and CEO of Cellerant. "We welcome them to the team and look forward to their important contributions to the development of cell products and cell-based therapies for life-threatening diseases including autoimmune disorders and cancer."

Dr. Timothy Fong comes to Cellerant from SangStat Medical Corporation where he was most recently Vice President, Discovery Research. Prior to SangStat, Dr. Fong held positions of increasing responsibility at Aventis Gencell, culminating with Head, Anti-Angiogenesis Program, Oncology. Dr. Fong has also held several management and research positions at Chiron Corporation. Dr. Fong received his Bachelor of Science from UCLA and his Master of Science in Biological Chemistry from the UCLA School of Medicine. He received his Ph.D. in Microbiology and Immunology from the UCLA School of Medicine. Dr. Fong completed postdoctoral work at The Salk Institute for Biological Studies and the University of California, San Diego. Dr. Fong is the author or co-author of numerous scientific articles and abstracts and he is the holder of multiple issued and pending patents.

Ms. Linda Rogers comes to Cellerant from SangStat Medical Corporation where she most recently held the position of Director, Clinical Operations. Prior to SangStat, Ms. Rogers was Director of Clinical Operations at Pharmacyclics. Ms. Rogers has provided independent consulting services in the areas of clinical project management, GCP and CRO management to several commercial operations and research and development-stage companies. Ms. Rogers has also held positions at Berlex Laboratories, Genentech, Inc., Searle Pharmaceuticals and Abbott Laboratories. Ms. Rogers received her R.N. from South Chicago Community Hospital School of Nursing, her Bachelor of Science from Barat College and her Master of Management from John Fitzgerald Kennedy University School of Management.

The Cellerant Therapeutics Leadership Team

Cellerant is building a world-class team composed of experienced individuals in its Management, Research and Development, and Clinical groups. Cellerant is led by Bruce Cohen, President and CEO, and Dr. Irving Weissman, a Director and Chair of the Scientific Advisory Board. Mr. Cohen has served in executive positions at several biotechnology companies including GeneSoft (acquired by Genome Therapeutics, now Oscient Pharmaceuticals), Acacia Biosciences (acquired by Rosetta Impharmatics and subsequently by Merck) and SEQUUS Pharmaceuticals (acquired by Alza and subsequently by Johnson & Johnson). Dr. Weissman is the Karel and Avice Beekhuis Professor of Cancer Biology, Pathology and Developmental Biology and Director of the Institute for Cancer/Stem Cell Biology and Medicine at Stanford University. In addition to his role as a scientific founder of Cellerant, Dr. Weissman has been recognized with numerous academic awards and appointments related to his research on the developmental biology, self-renewal, homing and functions of the cells that make up the blood-forming and immune systems.

Cellerant has attracted a top-level team of Directors, including George B. Rathmann, Ph.D., Chairman of Nuvelo and co-founder of Amgen; David Baltimore, Ph.D., President of the California Institute of Technology and winner of the 1975 Nobel Prize for his work in virology; and Stephen D. Greenberg, Managing Director at Allen & Company LLC. Cellerant's Medical and Scientific Advisory Board consists of individuals with recognized expertise in stem cell research, oncology, bone marrow transplantation and related fields.

About Cellerant Therapeutics

Cellerant Therapeutics Inc. (www.cellerant.com) is a clinical-stage biotechnology company developing and commercializing the use of hematopoietic (blood-forming) stem cell-based products and therapies for the treatment of a variety of autoimmune disorders, infectious disease and cancer. The company's extensive portfolio of intellectual property and clinical assets are licensed from Novartis and Stanford University. Cellerant's proprietary HSC technology is the basis for commercial applications in allogeneic transplantation, universal cell products, protein pharmaceuticals and T-cell therapy.